Implications of Bilateral Oophorectomy on Quality of Life and Sexual Function
DOI:
https://doi.org/10.18041/2390-0512/biociencias.2.13451Keywords:
Salpingo-oophorectomy, Hysterectomy, Female Sexual Dysfunction, Quality of Life, MenopauseAbstract
Objective: To compare quality of life (QoL) and sexual function in women undergoing hysterectomy with and without bilateral salpingo-oophorectomy. Materials and methods: An observational, analytical cohort study was conducted among women undergoing hysterectomy for benign indications; 137 patients underwent hysterectomy with bilateral salpingo-oophorectomy (H-BSO) and 295 underwent hysterectomy without salpingo-oophorectomy (H-WSO). Participants were recruited from three clinics in the Coffee Region (Eje Cafetero), Colombia, between 2019 and 2024. Sexual function was assessed using the Female Sexual Function Index (FSFI), and quality of life was evaluated with the Menopause Rating Scale (MRS). Hormonal levels were measured, and descriptive statistics were applied. Results: The mean age of participants was 46,35 ± 7,29 vs. 44,97 ± 8,5 years (p > 0.05). At the six-month follow-up, menopausal symptoms were significantly more frequent in the H-BSO group compared to the H-WSO group (91,97% vs. 30,16%; p < 0.05), with hot flashes and vaginal dryness being the most predominant. The total MRS score was higher in the H-BSO group, indicating greater impairment of quality of life (20,39 ± 7,95 vs. 13,79 ± 6,53; p < 0.05). The FSFI score was significantly lower in the H-BSO group compared to the H-WSO group (22,86 ± 9,47 vs. 27,58 ± 6,49), with a mean difference of -4.72 points (IC95%: −6,85 a −2,59; p = 0,003). Conclusions: Women undergoing hysterectomy with bilateral salpingo-oophorectomy exhibit poorer postoperative quality of life, a high prevalence of associated sexual dysfunction, and lower hormonal levels. Further research is warranted to elucidate the mechanisms underlying these associations.
Downloads
References
1) Wu JM, Wechter ME, Geller EJ, Nguyen TV, Visco AG. Hysterectomy rates in the United States, 2003. Obstet Gynecol. 2007 Nov;110(5):1091-5. doi: 10.1097/01.AOG.0000285997.38553.4b. PMID: 17978124.
2) Mytton J, Evison F, Chilton PJ, Lilford RJ. Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ. 2017 Feb 6;356:j372. doi: 10.1136/bmj.j372. PMID: 28167486; PMCID: PMC5421461.
3) Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol. 2009 May;113(5):1027-1037. doi: 10.1097/AOG.0b013e3181a11c64. PMID: 19384117; PMCID: PMC3791619.
4) Hassan H, Allen I, Sofianopoulou E, Walburga Y, Turnbull C, Eccles DM, Tischkowitz M, Pharoah P, Antoniou AC. Long-term outcomes of hysterectomy with bilateral salpingo-oophorectomy: a systematic review and meta-analysis. Am J Obstet Gynecol. 2024 Jan;230(1):44-57. doi: 10.1016/j.ajog.2023.06.043. Epub 2023 Jun 25. PMID: 37364803.
5) Evans EC, Matteson KA, Orejuela FJ, Alperin M, Balk EM, El-Nashar S, Gleason JL, Grimes C, Jeppson P, Mathews C, Wheeler TL, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. Obstet Gynecol. 2016 Sep;128(3):476-85. doi: 10.1097/AOG.0000000000001592. PMID: 27500347; PMCID: PMC5100819.
6) Moorman PG, Myers ER, Schildkraut JM, Iversen ES, Wang F, Warren N. Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol. 2011 Dec;118(6):1271-1279. doi: 10.1097/AOG.0b013e318236fd12. PMID: 22067716; PMCID: PMC3223258.
7) Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterectomy and menopause: a prospective cohort study. BJOG. 2005 Jul;112(7):956-62. doi: 10.1111/j.1471-0528.2005.00696.x. PMID: 15957999.
8) Farland LV, Rice MS, Degnan WJ 3rd, Rexrode KM, Manson JE, Rimm EB, Rich-Edwards J, Stewart EA, Cohen Rassier SL, Robinson WR, Missmer SA. Hysterectomy With and Without Oophorectomy, Tubal Ligation, and Risk of Cardiovascular Disease in the Nurses' Health Study II. J Womens Health (Larchmt). 2023 Jul;32(7):747-756. doi: 10.1089/jwh.2022.0207. Epub 2023 May 8. PMID: 37155739; PMCID: PMC10354306.
9) Chen Y, Li F, Liang L, Hua H, Liu S, Yu Z, Chen Q, Huang S, Qin P. Examining the association of hysterectomy with and without oophorectomy on cardiovascular disease and all-cause, cardiovascular or cancer mortality: A systematic review and meta-analysis. BJOG. 2024 Oct;131(11):1444-1455. doi: 10.1111/1471-0528.17843. Epub 2024 May 15. PMID: 38747094.
10) Tuesley KM, Protani MM, Webb PM, Dixon-Suen SC, Wilson LF, Stewart LM, Jordan SJ. Hysterectomy with and without oophorectomy and all-cause and cause-specific mortality. Am J Obstet Gynecol. 2020 Nov;223(5):723.e1-723.e16. doi: 10.1016/j.ajog.2020.04.037. Epub 2020 May 4. PMID: 32376318.
11) Espitia De La Hoz FJ. Prevalencia de disfunción sexual en mujeres del Eje Cafetero. Revista Ciencias Biomédicas. 2016;7(1): 25–33. https://doi.org/10.32997/rcb-2016-2908.
12) Casiano ER, Trabuco EC, Bharucha AE, Weaver AL, Schleck CD, Melton LJ 3rd, Gebhart JB. Risk of oophorectomy after hysterectomy. Obstet Gynecol. 2013 May;121(5):1069-1074. doi: 10.1097/AOG.0b013e31828e89df. PMID: 23635745; PMCID: PMC3810957.
13) Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208. doi: 10.1080/009262300278597. PMID: 10782451.
14) Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20. doi: 10.1080/00926230590475206. PMID: 15841702.
15) Espitia-De La Hoz FJ. Prevalence and characterisation of sexual dysfunctions in women, in12 colombian cities, 2009-2016. Rev Colomb Obstet Ginecol. 2018; 69(1):9-21. DOI:10.18597/rcog.303511.
16) Hauser GA, Huber IC, Keller PJ, Lauritzen C, Schneider HP. Evaluation der klimakterischen Beschwerden (Menopause Rating Scale [MRS]) [Evaluation of climacteric symptoms (Menopause Rating Scale)]. Zentralbl Gynakol. 1994;116(1):16-23. German. PMID: 8147175.
17) Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003 Jul 30;1:28. doi: 10.1186/1477-7525-1-28. PMID: 12914663; PMCID: PMC183844.
18) Espitia De La Hoz FJ. Calidad de vida en mujeres con síndrome genitourinario de la menopausia en el Quindío, Colombia. Rev Colomb Endocrinol Diabet Metab. 2023;10(1):e761. https://doi.org/10.53853/encr.10.1.761.
19) Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F, Heinemann LA, Do MT. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes. 2004 Sep 2;2:45. doi: 10.1186/1477-7525-2-45. PMID: 15345062; PMCID: PMC516787.
20) Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes. 2004 Nov 22;2:67. doi: 10.1186/1477-7525-2-67. PMID: 15555079; PMCID: PMC534786.
21) Sheather J. Declaration of Helsinki puts global justice up front. BMJ. 2024 Nov 1;387:q2405. doi: 10.1136/bmj.q2405. PMID: 39486836.
22) Benshushan A, Rojansky N, Chaviv M, Arbel-Alon S, Benmeir A, Imbar T, Brzezinski A. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric. 2009 Oct;12(5):404-9. doi: 10.1080/13697130902780846. PMID: 19479488.
23) Alexandre M, Black J, Whicker M, Minkin MJ, Ratner E. The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors". Maturitas. 2017 Nov;105:46-51. doi: 10.1016/j.maturitas.2017.06.003. Epub 2017 Jun 3. PMID: 28602465.
24) Gosset A, Susini M, Vidal F, Tanguy-Le-Gac Y, Chantalat E, Genre L, Trémollières F. Quality of life of patients with bilateral oophorectomy before the age of 45 for the treatment of endometriosis. Maturitas. 2022 Aug;162:52-57. doi: 10.1016/j.maturitas.2022.04.005. Epub 2022 Apr 29. PMID: 35561587.
25) Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol Oncol. 2016 Jan;140(1):101-6. doi: 10.1016/j.ygyno.2015.11.016. Epub 2015 Nov 18. PMID: 26597462.
26) Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2016 Jan;140(1):95-100. doi: 10.1016/j.ygyno.2015.11.002. Epub 2015 Nov 3. PMID: 26545955.
27) Zimmerman J, Brännström M, Bergdahl C, Aziz A, Hermansson J. Long-Term Follow Up of Sexual Function and Steroid Levels in Women after Perimenopausal Hysterectomy with or without Concomitant Oophorectomy. J Clin Med. 2023 Jul 28;12(15):4976. doi: 10.3390/jcm12154976. PMID: 37568378; PMCID: PMC10419815.
28) Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology. 2001 May-Jun;10(3):231-41. doi: 10.1002/pon.512. PMID: 11351375.
29) Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res. 2011 Mar 16;1379:188-98. doi: 10.1016/j.brainres.2010.10.031. Epub 2010 Oct 18. PMID: 20965156; PMCID: PMC3046246.
30) Stanczyk FZ, Chaikittisilpa S, Sriprasert I, Rafatnia A, Nadadur M, Mishell DR Jr. Circulating androgen levels before and after oophorectomy in premenopausal and postmenopausal women. Climacteric. 2019 Apr;22(2):169-174. doi: 10.1080/13697137.2018.1535584. Epub 2019 Jan 7. PMID: 30612472.
31) Jain SH, Somalwar SA. Analysis of Prophylactic Salpingo-oophorectomy at the Time of Hysterectomy for Benign Lesions. J Midlife Health. 2019 Jan-Mar;10(1):29-32. doi: 10.4103/jmh.JMH_70_18. PMID: 31001053; PMCID: PMC6459073.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Biociencias
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
